Renal protective effect after administration of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients and chronic kidney disease with normoalbuminuria

Renal protective effect after administration of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients and chronic kidney disease with normoalbuminuria - Renal protective effect after administration of SGLT2 inhibitors in atypical DKD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000040424

Enrollment

Registered

2020-05-19

Start date

2020-05-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes and CKD (eGFR < 60 mL/min/1.73 m2) with normoalbuminurea (urine albumin to creatinine ratio (UACR) < 30 mg/g Cr and/or urinary protein to creatinine ratio (UPCR) < 150 mg/g Cr)

Exclusion criteria

Exclusion criteria: 1)type 1 diabetes 2)taking glucagon-like peptide-1 receptor agonists for type 2 diabetes 3)endocrine disease 4)taking steroid or immunosuppressant for autoimmune disease 5)dialysis, transplantation 6)liver cirrhosis and malignancy

Design outcomes

Primary

Measure	Time frame
to assess the clinical effectiveness of SGLT2is on renal function by analyzing the change in eGFR at 1 years after initiating SGLT2 inhibitor compare with that in conventional antidiabetic medication	—

Secondary

Measure	Time frame
to investigate the variables associated with the change in eGFR at 1 years after initiating SGLT2 inhibitor	—

Countries

Japan

Contacts

Public ContactKiyohiko Takahashi

Obihiro-Kosei General Hospital Third Department of Internal Medicine

kiyopon19840330@yahoo.co.jp0155-65-0101

Outcome results